A business-oriented Interview with the president of Vero Bioscience:
In this Q&A, you’ll hear from Paul Coletta, co-founder and CEO of Vero Bioscience, a precision health platform measuring and optimizing organ health for longevity. Paul explains how breakthrough proteomics and AI unlock life-changing interventions, all from a simple at-home blood test.
Tell us about Vero.
Paul Coletta: Vero is redefining how we understand and measure health, before disease begins. We’ve built a precision health platform that uses advanced proteomics and AI to assess the biological age and function of your organs.
Unlike typical diagnostics that tell you what’s broken, Vero looks for the earliest signals of change so we can intervene before things fall apart.
From a simple at-home blood test, we measure over 5K proteins, compare them to healthy patterns, and tell you which organs are aging faster than they should. From there, we recommend specific interventions, lifestyle changes, supplements, or therapeutics to help optimize that organ’s health.
Our motto: You’re only as healthy as your oldest organ.
What’s next on the roadmap?
PC: We’re launching our beta program this summer with select clinics and early adopters. Our goal is to validate efficacy across multiple organ systems, showing measurable improvement in biological age with targeted interventions.
We’re also building out our digital experience with reports but, more importantly, with ongoing health coaching powered by AI.
Long term, Vero becomes a recurring health loop: test, assess, intervene, retest. Eventually, it will include a curated marketplace of validated interventions. It’s the at-home AI health clinic, starting with your blood.
Read the full interview:
